Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
A Gastronomic Experience in Healthy Enjoyments: A Survey of \Nutritious and Tasty\ Solid Cooking Recipe Book11.08.2023 - 2Exploring School Life: Self-awareness and Illustrations25.09.2023
- 3Civil rights leader Jesse Jackson hospitalized, family requests prayers12.11.2025
- 4More loons are filling Maine's lakes with their ghostlike calls13.12.2025
- 5Watch interstellar comet 3I/ATLAS make its closest approach to Earth in free livestream on Dec. 1817.12.2025
- The most effective method to Decide the Best Auto Crash Attorney for Your Lawful Necessities
- Step by step instructions to Pick the Right Dental specialist for Your Dental Inserts Technique
- A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- 5 Cell phones of the Year
- South Korea to End Bear Bile Farming and Find New Homes for the 200 Bears Stuck in the Industry
- Faulty glucose monitors linked to 7 deaths and more than 700 injuries, FDA warns
- What you need to know about Trump accounts as Michael and Susan Dell donate $6 billion to the new early childhood investment program
- 10 Energizing Vocations in the Innovation Business
- Figure out How to Acquire Rewarding Open Record Rewards
